Obstructive sleep apnea (OSA) is associated with various negative health consequences including increased risk of heart disease, hypertension and daytime sleepiness causing road accidents. The economic burden of OSA is rising as almost 1 billion people worldwide are estimated to have OSA. The current diagnostic metric, however, relates poorly to these symptoms and comorbidities. It merely measures the frequency of breathing cessations without assessing OSA severity in any other physiologically relevant way. Furthermore, the clinical methods for analyzing PSG signals are outdated, expensive and laborious. Due to this, the majority of OSA patients remain without diagnosis or have an inaccurate diagnosis leading to sub-optimal treatment. Thus, it is evident that more personalized diagnostics are required including predictive and preventive health care and patient participation. The SLEEP REVOLUTION aims to develop machine learning techniques to better estimate OSA severity and treatment needs to improve health outcomes and quality of life. These techniques are implemented to high-end wearables developed in this project to alleviate the costs and increase the availability of PSGs. Finally, we aim to design a digital platform that functions as a bridge between researchers, patients and healthcare professionals. We will achieve these ambitious goals throughout extensive collaboration between sleep specialists, computer scientists and industry partners. The collaboration network consists of over 30 sleep centers working together to provide the needed retrospective data (over 10.000 sleep studies). The multi-center prospective trials involve experts and end-users to assess and validate the new SLEEP REVOLUTION diagnostic algorithms, wearables and platforms. With the commitment of the European Sleep Research Society and Assembly of National Sleep Societies (over 8000 members), we have the unique possibility to create new standardized guidelines for sleep medicine in the EU.

1 in 3 adults are prediabetic – at increased risk for type-2 diabetes, heart attack and stroke. Diabetes is associated with a high individual, social and economic burden. The global expenditure on diabetes was estimated to be €508 billion in 2015. The average diabetes-associated expenditure per adult person with diabetes in the EU in 2015 was placed at just over €2,640. In recognition of this challenge, many countries in Europe have introduced national plans addressing diabetes specifically (national diabetes plans, NDPs). GoodlifeMe was founded in 2013 in Iceland by two medical doctors who had worked for years treating people with lifestyle diseases. As 86% of deaths are due to lifestyle-related diseases, their passion was to prevent these diseases rather than treat their consequences. The company employs 11 full-time professionals including MDs, MBA, seasoned sales and marketing executives, a biomedical engineer, designer and software/game developers. The unique combination of our team has led to SIDEKICKHEALTH: a simple helper for lifestyle change for the not-so-motivated or health-savvy, those who are worst hit by lifestyle problems like prediabetes. Drawing on lessons from behavioural economics, the product is simple, fun, graphical, colourful, rich in challenges & competitions, and altruistic rewards (e.g. allowing users to earn clean water for children in need by doing well in the program). SidekickHealth has been developed applying scientific and medical methods from day one. The results have been validated through clinical trials, most recently with Harvard University. It has already signed initial contracts with Diabetes Prevention Programs to use Sidekick as a digital layer for their treatments. The results show increased performance in all indicators, including 190% of patients are more likely to reach weight loss goals. Given that the income of the provider is success-based, we are providing 65% increased revenue to our clients.